Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Interindividual variability in sensitivity to warfarin--Nature or nurture?

Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D.

Clin Pharmacol Ther. 2001 Aug;70(2):159-64.

PMID:
11503010
2.

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H.

Clin Pharmacol Ther. 2003 Mar;73(3):253-63.

PMID:
12621390
3.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
4.

Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.

Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr.

J Clin Pharmacol. 2001 Jul;41(7):715-22.

PMID:
11452703
5.
6.

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Redman AR.

Pharmacotherapy. 2001 Feb;21(2):235-42. Review.

PMID:
11213860
8.

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, Kimura S, Kanamori M, Echizen H.

Clin Pharmacol Ther. 2000 Nov;68(5):541-55.

PMID:
11103757
9.

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H.

Clin Pharmacol Ther. 2004 Mar;75(3):204-12.

PMID:
15001972
11.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
12.

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.

Hermida J, Zarza J, Alberca I, Montes R, López ML, Molina E, Rocha E.

Blood. 2002 Jun 1;99(11):4237-9.

14.

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.

Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V.

Pharmacogenomics J. 2005;5(3):193-202.

PMID:
15824753
15.

Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.

Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE.

J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):143-8.

PMID:
9686881
16.

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.

Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.

Clin Pharmacol Ther. 1998 May;63(5):519-28.

PMID:
9630825
17.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
18.

Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.

Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H, Yasumori T, Echizen H.

Clin Pharmacol Ther. 1999 Dec;66(6):569-81.

PMID:
10613612
19.

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G.

Thromb Haemost. 2000 Nov;84(5):775-8.

PMID:
11127854
20.

Supplemental Content

Support Center